Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 219
Filter
Add more filters

Publication year range
1.
Science ; 194(4261): 184-6, 1976 Oct 08.
Article in English | MEDLINE | ID: mdl-959845

ABSTRACT

Organochlorine residues in the fat of young Mexican free-tailed bats, Tadarida brasiliensis, reached the brain and caused symptoms of poisoning after the fat mobilization that takes place during migratory flight was simulated. These chemical body burdens were obtained naturally under free-living conditions at the maternity roost. The data obtained support the hypothesis that pesticides have contributed to recent declines in populations of this bat.


Subject(s)
Chiroptera/physiology , Adipose Tissue/metabolism , Age Factors , Animals , Brain/drug effects , Brain/metabolism , Flight, Animal , Hydrocarbons, Chlorinated , Insecticides/metabolism , Insecticides/toxicity , Physical Exertion
2.
J Clin Invest ; 51(5): 1051-7, 1972 May.
Article in English | MEDLINE | ID: mdl-4341500

ABSTRACT

The changes in other plasma lipoproteins which accompany alterations in very low density lipoproteins (VLDL) were studied in 31 normal and hyperlipidemic men and women who underwent weight reduction, carbohydrate induction, or clofibrate treatment. Plasma lipids and individual lipoprotein cholesterol concentrations were measured serially during control and treatment periods. Low density lipoprotein (LDL) protein was determined by radial immunodiffusion. Oppositely directed changes in VLDL and LDL were found with each of the three metabolic perturbations. Changes in high density lipoprotein (HDL) cholesterol generally paralleled those in LDL but were less consistent. Two patients with type III hyperlipoproteinemia failed to demonstrate reciprocal increases in LDL despite more than 40% reduction in plasma glycerides or VLDL with weight reduction or clofibrate therapy. After clofibrate therapy, LDL increased in proportion to the absolute decrease in VLDL cholesterol during treatment. LDL protein changed relatively less than did LDL cholesterol. The mechanism for the interdependency of plasma VLDL and LDL concentrations over the long term is not known and may be the result of altered rates of interconversion of these lipoproteins, or to feedback inhibition by VLDL of LDL production and release.


Subject(s)
Hyperlipidemias/blood , Lipoproteins/blood , Adolescent , Adult , Angina Pectoris/blood , Body Weight , Cholesterol/blood , Clofibrate/therapeutic use , Coronary Disease/blood , Female , Glycerides/blood , Humans , Hyperlipidemias/drug therapy , Immunodiffusion , Lipoproteins, HDL/blood , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/blood , Lipoproteins, LDL/metabolism , Lipoproteins, VLDL/blood , Lipoproteins, VLDL/metabolism , Male , Middle Aged , Myocardial Infarction/blood , Obesity/blood
3.
J Clin Invest ; 51(9): 2472-81, 1972 Sep.
Article in English | MEDLINE | ID: mdl-4344733

ABSTRACT

To investigate the interaction of lipoproteins with semipermeable membranes, solutions of low density lipoproteins (LDL), very low density lipoproteins (VLDL), mixtures of the two, and diluted, normal, and hyperlipidemic serum were ultrafiltered through a synthetic membrane (500 A nominal pore diameter) using a stirred laboratory ultrafiltration cell. The pressure dependence of ultrafiltrate flux showed that a concentrated layer of lipoproteins was built up at the membrane surface (concentration polarization) and that VLDL was more subject to polarization than LDL. This phenomenon controlled the observed lipoprotein transport behavior. Whereas true membrane rejection (the fraction of the solute on the membrane surface which does not pass through the membrane) was greater than 0.95 for both LDL and VLDL, observed solute rejection varied from nearly 0 to 1.0, depending upon experimental conditions. If concentration polarization occurs in the arterial system, these results suggest that lipoprotein transport into arterial wall may be influenced not only by arterial blood pressure and the properties of the arterial wall, but also by local hemodynamic conditions and by the relative as well as absolute magnitudes of LDL and VLDL concentration.


Subject(s)
Arteriosclerosis/etiology , Lipoproteins/analysis , Cholesterol/analysis , Dialysis , Edetic Acid , Humans , Hydrostatic Pressure , Hyperlipidemias/blood , Lipoproteins, LDL/analysis , Lipoproteins, LDL/blood , Lipoproteins, LDL/isolation & purification , Lipoproteins, VLDL/analysis , Lipoproteins, VLDL/blood , Lipoproteins, VLDL/isolation & purification , Mathematics , Membranes, Artificial , Methods , Proteins/analysis , Triglycerides/analysis , Ultracentrifugation , Ultrafiltration
4.
J Clin Invest ; 92(1): 203-11, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8325986

ABSTRACT

A proband with chylomicronemia, pancreatitis, and non-insulin-dependent diabetes (NIDDM) bears two different mutations in exon 3 of the lipoprotein lipase (LPL) gene: a missense mutation, 75Arg-->Ser, inherited through the paternal line and a truncation, 73Tyr-->Ter, through the maternal line. NIDDM appeared to be independently segregating. The R75S mutant was studied in extracts and media from transfected COS-1 cells. Detectable amounts of catalytically competent R75S LPL suggested destabilization of the active homodimer as with exon 5 mutants (Hata et al. 1992. J. Biol. Chem. 267:20132-20139). Hydrolysis of a short-chain fatty acid ester indicated that R75S does not directly affect activation of LPL by apoC-II. Subjects with NIDDM and wild-type LPL, and nondiabetic middle-aged carriers of the 73Tyr-->Ter truncation had moderate hypertriglyceridemia (260-521 mg/dl) and reduced high density lipoprotein cholesterol. A maternal aunt with NIDDM carried the truncation. Her phenotype (triglycerides of 5,300 mg/dl, eruptive xanthomatosis, and recurrent pancreatitis) was as severe as that in homozygotes or compound heterozygotes. We conclude: (a) diabetic carriers of dysfunctional LPL alleles are at risk for severe lipemia; and (b) the physiologic defects in NIDDM may be additive or synergistic with heterozygous LPL deficiency.


Subject(s)
Diabetes Mellitus, Type 2/genetics , Hyperlipoproteinemia Type I/genetics , Hypertriglyceridemia/genetics , Lipoprotein Lipase/genetics , Pancreatitis/genetics , Adolescent , Adult , Aged , Alleles , Base Sequence , Child , Exons , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Mutation , Oligodeoxyribonucleotides/chemistry , Pedigree
5.
J Clin Invest ; 86(3): 735-50, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2394828

ABSTRACT

Familial lipoprotein lipase (LPL) deficiency is a rare genetic disorder accompanied by well-characterized manifestations. The phenotypic expression of heterozygous LPL deficiency has not been so clearly defined. We studied the pedigree of a proband known to be homozygous for a mutation resulting in nonfunctional LPL. Hybridization of DNA from 126 members with allele-specific probes detected 29 carriers of the mutant allele. Adipose tissue LPL activity, measured previously, was reduced by 50% in carriers, but did not reliably distinguish them from noncarriers. Carriers were prone to the expression of a form of familial hypertriglyceridemia characterized by increased plasma triglyceride, VLDL cholesterol and apolipoprotein B, and decreased LDL and HDL cholesterol concentrations. These manifestations were age modulated, with conspicuous differences between carriers and noncarriers observed only after age 40. Several noncarriers exhibited similar lipid abnormalities, but without the inverse relationship between VLDL cholesterol and LDL cholesterol noted among carriers. In addition to age and carrier status, the potentially reversible conditions, obesity, hyperinsulinemia and lipid-raising drug use were contributory. Thus heterozygous lipoprotein lipase deficiency, together with age-related influences, may account for a form of familial hypertriglyceridemia.


Subject(s)
Lipoprotein Lipase/genetics , Adipose Tissue/enzymology , Adult , Age Factors , Aged , Base Sequence , Child , Cholesterol, HDL/metabolism , Cholesterol, LDL/metabolism , Cholesterol, VLDL/metabolism , Diabetes Complications , Discriminant Analysis , Female , Heterozygote , Humans , Lipoprotein Lipase/deficiency , Male , Middle Aged , Molecular Sequence Data , Multivariate Analysis , Mutation , Obesity/genetics , Oligonucleotides , Pedigree , Phenotype , Polymerase Chain Reaction , Regression Analysis , Sex Factors , Triglycerides/blood
6.
J Natl Cancer Inst ; 64(2): 241-8, 1980 Feb.
Article in English | MEDLINE | ID: mdl-6243715

ABSTRACT

The herpes simplex virus type-2 (HSV-2)-transformed human cell line HB-2-3 was fused with thymidine kinase (TK)-deficient mouse cells [LM(TK-)], and 12 independent hybrids were isolated with the use of the HAT (hypoxanthine, amethopterin, and thymidine)-ouabain selection system. Discontinuous polyacrylamide gel electrophoresis studies demonstrated that the HSV-2-specific TK was the selected enzyme in the hybrids. Isoenzyme analysis and karyotyping were used in the analysis of the hybrids for the presence of human chromosomes. All 12 hybrids contained human chromosome No. 18 and the enzyme peptidase A, which is encoded by a gene on this chromosome. Hybrids were exposed to bromodeoxyuridine (BrdUrd) as a means of selection for cells that had lost HSV-2 TK activity. Isoenzyme and karyotyping data obtained from 33 BrdUrd-resistant sublines were consistent with the hypothesis that the HSV-2 TK gene is associated with chromosome No. 18 in the HB-2-3 cell line.


Subject(s)
Cell Transformation, Viral , Chromosomes, Human, 16-18 , Genes, Viral , Simplexvirus/genetics , Thymidine Kinase/genetics , Animals , Bromodeoxyuridine/pharmacology , Clone Cells/drug effects , Drug Resistance , Humans , Hybrid Cells/enzymology , Mice , Simplexvirus/enzymology
7.
Biochim Biophys Acta ; 893(3): 470-9, 1987 Oct 07.
Article in English | MEDLINE | ID: mdl-3651445

ABSTRACT

Upon the addition of inorganic phosphate, isolated rat-heart mitochondria released endogenous adenine nucleotides. To elucidate the mechanism of this phosphate-induced efflux, we evaluated the relative roles of three inner mitochondrial membrane carriers: the adenine nucleotide translocase, the phosphate/hydroxyl exchanger, and the dicarboxylate carrier. Atractyloside (a specific inhibitor of the adenine nucleotide translocase) prevented this efflux, but did not inhibit mitochondrial swelling. Inhibitors of the phosphate/hydroxyl exchanger (200 microM n-ethylmaleimide and 10 microM mersalyl) did not inhibit phosphate-induced efflux. 200 microM mersalyl (which inhibited both the phosphate/hydroxyl exchanger and the dicarboxylate carrier) inhibited the rate of efflux approx. 65% Phenylsuccinate and 2-n-butylmalonate (inhibitors of the dicarboxylate carrier) partially inhibited phosphate-induced efflux and adenine nucleotide translocase activity. Mersalyl (200 microM) had no effect on adenine nucleotide translocase activity. Partial inhibition of the adenine nucleotide translocase by phenylsuccinate and butylmalonate could not explain the extent of inhibition of phosphate-efflux by these agents. Moreover, the rates of adenine nucleotide efflux in the presence of phenylsuccinate, butylmalonate, or mersalyl correlated well with the ability of these agents to inhibit succinate-supported respiration. We conclude that phosphate-induced efflux of adenine nucleotides from rat heart mitochondria occurs over the adenine nucleotide translocase, and that the site of action of the phosphate is not the phosphate/hydroxyl exchanger, but is likely the dicarboxylate carrier.


Subject(s)
Adenine Nucleotides/metabolism , Carrier Proteins/metabolism , Mitochondria, Heart/metabolism , Phosphates/pharmacology , Animals , Atractyloside/pharmacology , Dicarboxylic Acid Transporters , Ethylmaleimide/pharmacology , Hydroxides/metabolism , Kinetics , Male , Malonates/pharmacology , Mersalyl/pharmacology , Mitochondria, Heart/drug effects , Mitochondrial ADP, ATP Translocases/antagonists & inhibitors , Oxygen Consumption/drug effects , Rats , Rats, Inbred Strains , Succinates/metabolism , Succinates/pharmacology , Succinic Acid
8.
Biochim Biophys Acta ; 922(3): 247-58, 1987 Dec 14.
Article in English | MEDLINE | ID: mdl-3689810

ABSTRACT

Retinyl ester concentrations in plasma from fasting humans, rabbits and rats are usually negligible. In contrast, plasma from fasting dogs contains appreciable amounts of retinyl esters, associated almost entirely with the low-density lipoproteins. This study was undertaken to gather additional information about the nature and origin of canine retinyl ester-containing lipoproteins. We examined the metabolism of endogenous lipoprotein retinyl esters in adult mongrel dogs with moderate vitamin A deficiency. Four animals were fed a diet of oatmeal and tuna fish that provided only 4% of the vitamin A contained in their control rations (15 vs. 367% of the canine recommended daily intake). There was an initial rapid decline in plasma retinyl esters. However, measurable concentrations persisted in plasma for up to 1 year of restricted vitamin A intake. Total plasma retinyl ester concentrations after 6 months of vitamin A deprivation, extrapolated from best-fit monoexponential decay curves for each animal, ranged from 11 to 89% of control, suggesting that there was sustained secretion of retinyl esters from endogenous stores. Density gradient ultracentrifugation of plasma from fasting vitamin A-deprived dogs showed retinyl esters in the very-low- and low-density lipoproteins. After fat and vitamin A feeding retinyl esters appeared among the very-low-, intermediate- and low-density lipoproteins, consistent with the suggestion that chylomicron retinyl esters are first taken up by the liver, and then resecreted as density less than 1.006-1.063 g/ml lipoproteins. Maximal incorporation of dietary retinyl esters into low-density lipoproteins was not reached until 24-48 h. Intermediate-density and beta-migrating low-density lipoprotein retinyl esters were increased markedly in fasting animals maintained on cholesterol- and saturated fat-enriched diets. These observations provide further evidence for the proposal that the canine liver secretes retinyl ester-containing particles, in amounts governed by dietary composition and vitamin A content. What selective advantage this unusual transport pathway might provide is not apparent.


Subject(s)
Cholesterol, Dietary/pharmacology , Lipoproteins, LDL/blood , Lipoproteins/blood , Retinol-Binding Proteins/blood , Vitamin A Deficiency/metabolism , Animals , Chromatography, High Pressure Liquid , Dietary Fats/administration & dosage , Dietary Fats/pharmacology , Dogs , Humans , Lipoproteins, HDL/blood , Rabbits , Rats , Retinol-Binding Proteins, Plasma , Retinyl Esters , Species Specificity
9.
J Clin Oncol ; 7(10): 1573-7, 1989 Oct.
Article in English | MEDLINE | ID: mdl-2789275

ABSTRACT

Reversible acute hypocholesterolemia was observed during treatment of metastatic cancer with high-dose intravenous recombinant interleukin-2 (IL-2). Further analysis revealed virtual disappearance of high-density lipoproteins (HDLs) and marked reduction in the concentration of low-density lipoproteins (LDL); the remaining LDL and intermediate-density lipoproteins (IDL) were enriched in triglyceride relative to cholesterol and had broad-beta electrophoretic mobility, properties reminiscent of remnant lipoproteins. These changes differ qualitatively and quantitatively from those previously reported for other cytokines such as tumor necrosis factor (TNF) or the interferons (IFNs).


Subject(s)
Cholesterol/blood , Interleukin-2/adverse effects , Metabolic Diseases/chemically induced , Humans , Kidney Neoplasms/therapy , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Melanoma/therapy , Metabolic Diseases/blood , Recombinant Proteins , Triglycerides/blood
10.
Diabetes ; 36(4): 485-90, 1987 Apr.
Article in English | MEDLINE | ID: mdl-3817303

ABSTRACT

Although lipoprotein lipase (LPL) is believed to be rate limiting in the catabolism of triglyceride-rich lipoproteins, LPL activity has not correlated with plasma triglyceride concentrations in experimental rat diabetes. To gather more information about this enzyme system in diabetes, LPL activities were measured in representative tissues from control and streptozocin-induced diabetic rats fed fat-free chow and in 48-h-starved animals. The DNA content of each tissue was determined so that LPL activity could be expressed in a way that was unaffected by tissue wasting. Diabetic animals lost approximately 20% of their body mass. Adipose tissue and soleus muscle cell masses were reduced, and there was marked fat atrophy at necropsy. Adipose tissue LPL was decreased in both starved and diabetic animals, whereas skeletal muscle activities were variably affected. Lipase content and distribution among the individual organs were calculated with published data for rat carcass composition. In diabetic rats, total LPL (adipose tissue, muscle, and parenchymal organs) was reduced by nearly two-thirds so that skeletal muscle became the predominant source of LPL. Ketonuria was less frequent in diabetic than in starved rats (P less than .018) despite their severe wasting. Serum triglyceride concentrations were higher in ketonuric than nonketonuric diabetic animals, and severe hypertriglyceridemia was seen exclusively in heavily ketonuric animals. These observations together with published information suggest that plasma triglyceride concentrations in the rat model are determined by a complex interplay between very-low-density lipoprotein synthesis, the capacity of the LPL removal system, properties of the lipoprotein substrate, and other unidentified factors.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Ketone Bodies/urine , Lipoprotein Lipase/metabolism , Starvation/metabolism , Triglycerides/blood , Adipose Tissue/enzymology , Animals , Blood Glucose/analysis , Body Weight , Diabetes Mellitus, Experimental/enzymology , Liver/enzymology , Male , Muscles/enzymology , Myocardium/enzymology , Rats , Rats, Inbred Strains , Starvation/enzymology
11.
Diabetes ; 35(8): 933-42, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3732634

ABSTRACT

The effects of diabetes on plasma lipoproteins were examined in a cohort of control and streptozocin-alloxan diabetic beagles fed either standard rations or an atherogenic cholesterol-supplemented diet. Lipoprotein cholesterol, triglyceride, and retinyl ester concentrations were measured in fractions separated by density gradient ultracentrifugation. Individual lipoprotein classes and apolipoproteins were assessed by electrophoresis. Postheparin plasma lipoprotein triglyceride lipase activities were also examined. In the absence of added dietary cholesterol, diabetic animals became hypercholesterolemic with relatively increased low-density (LDL) and decreased high-density (HDL) lipoprotein cholesterol concentrations. Apolipoprotein E-containing beta- to alpha 2-migrating HDL1 (HDLc) appeared in rho = 1.020-1.080 g/ml subfractions, whereas alpha 1-migrating typical HDL (rho = 1.06-1.21 g/ml) was reduced. In comparison to nondiabetic cholesterol-fed animals, diabetic cholesterol-fed animals had increased cholesterol (but not triglyceride) concentrations in very-low- and intermediate-density classes. These classes contained retinyl esters and low-molecular-weight apolipoprotein B (components of intestinal lipoprotein remnants) as well as apolipoprotein E and high-molecular-weight apolipoprotein B. These findings could not be explained by decreased postheparin plasma lipoprotein lipolytic activities. Increased plasma concentrations of HDLc in poorly controlled diabetic dogs may reflect a pathologic disturbance in the excretory limb of cholesterol transport from peripheral cells to the liver. In addition, exaggerated retention of lipoprotein remnants in cholesterol-fed diabetic dogs may contribute to increased delivery of cholesterol to extrahepatic tissues. This model appears to be suitable for physiologic studies of the effects of diabetes on reverse cholesterol transport.


Subject(s)
Apolipoproteins E/blood , Diabetes Mellitus, Experimental/blood , Lipoproteins/blood , Animals , Blood Glucose/analysis , Blood Urea Nitrogen , Cholesterol/blood , Cholesterol, Dietary/pharmacology , Dogs , Electrophoresis, Agar Gel , Humans , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood
12.
Diabetes ; 40(12): 1630-9, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1756903

ABSTRACT

We previously reported that dog diabetes results in hypercholesterolemia and the accumulation of a high-density lipoprotein (HDL) subclass, HDL1. Hypercholesterolemic diabetic rodents exhibit hyperphagia, intestinal hypertrophy, and increased intestinal cholesterol synthesis and absorption; intestinal 3-hydroxy-3-methylglutaryl (HMG) CoA reductase activity is increased, whereas hepatic activity is unchanged or reduced. To determine whether similar mechanisms operate in the hypercholesterolemic diabetic dog, we measured hepatic and intestinal cholesterologenesis. Streptozocin-alloxan-induced diabetic dogs allowed access to food ad libitum were hyperphagic and hypercholesterolemic (10.1 vs. 4.47 mM) but normotriglyceridemic. Plasma HDL1 concentrations were markedly increased. Differences in renal and hepatic function were not statistically significant, except serum alkaline phosphatase, which was elevated 4-fold (P = 0.0003). Urinary mevalonate, an index of whole-body cholesterol synthesis, was increased 6-fold. Intestinal and hepatic weights were both increased, and direct measurements showed crypt and villus thickening. The activity of HMG CoA reductase per gram organ weight was increased 1.7-fold in liver and 2.1-fold in intestine. Calculated whole-organ activity in intestine was nearly twice that in liver. These observations provide strong evidence that intestinal cholesterogenesis is involved in the pathogenesis of hypercholesterolemia in dog diabetes and support the conclusion that increased cholesterol synthesis plays a role in the hypercholesterolemia of diabetes.


Subject(s)
Cholesterol/metabolism , Diabetes Mellitus, Experimental/physiopathology , Hydroxymethylglutaryl CoA Reductases/metabolism , Hypercholesterolemia/physiopathology , Intestinal Mucosa/metabolism , Intestine, Small/metabolism , Lipoproteins/blood , Liver/metabolism , Animals , Body Weight , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Dogs , Female , Hypercholesterolemia/etiology , Insulin/therapeutic use , Intestinal Mucosa/pathology , Intestine, Small/pathology , Lipoproteins/isolation & purification , Male , Mevalonic Acid/urine , Models, Biological , Organ Size
13.
Arch Intern Med ; 135(5): 733-5, 1975 May.
Article in English | MEDLINE | ID: mdl-150825

ABSTRACT

A patient developed cholestatic hepatitis while being treated with nitrofurantoin. A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime. It is important to consider possible cross-sensitivity of chemically related compounds even when they are administered by different routes.


Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Cholestasis/chemically induced , Nitrofurantoin/adverse effects , Adult , Diabetes Complications , Drug Eruptions/etiology , Female , Humans , Nitrofurantoin/administration & dosage , Nitrofurantoin/therapeutic use , Urinary Tract Infections/drug therapy
14.
Diabetes Care ; 6(6): 604-7, 1983.
Article in English | MEDLINE | ID: mdl-6360601

ABSTRACT

Personal microcomputers are becoming available to millions of individuals. Inevitably this new technology will be applied in a variety of ways to the routine management of diabetes. In this article we present the results of a pilot effort which shows that large cumbersome sets of blood glucose data, obtained by conventional self-monitoring techniques, can be stored, analyzed, and displayed conveniently with a home microcomputer. This technique has potential value for the identification of long-term trends in blood glucose regulation.


Subject(s)
Blood Glucose/analysis , Computers , Diabetes Mellitus/blood , Microcomputers , Monitoring, Physiologic , Self Care , Adult , Data Display , Humans , Insulin/therapeutic use
15.
J Clin Endocrinol Metab ; 57(3): 517-23, 1983 Sep.
Article in English | MEDLINE | ID: mdl-6348062

ABSTRACT

Previous studies have suggested that reduction of dietary fat intake, with or without caloric restriction, may lead to improvement in certain of the characteristic abnormalities that accompany total lipodystrophy (TLD). We have studied the effects of eucaloric medium chain triglyceride (MCT) substitution for dietary long chain fatty acids in a patient with acquired total lipodystrophy and unusual somatic and visceral anomalies. The patient exhibited insulin resistance, carbohydrate intolerance, striking fasting- and glucose-stimulated hyperinsulinemia, hyperglucagonemia, type V hyperlipoproteinemia, and lipoprotein lipase deficiency on a normal diet. Improvement in chylomicronemia, hypertriglyceridemia, and xanthomatosis occurred during eucaloric MCT substitution. Carbohydrate intolerance decreased and fasting immunoreactive glucagon and insulin concentrations fell 37% and 83%, respectively. Plasma triglyceride polyunsaturated fatty acid concentrations decreased to very low levels. With long term MCT feeding supplemented by polyunsaturated fatty acids, hepatomegaly has gradually decreased, while body weight has remained stable. The patient has not yet required insulin therapy. These observations suggest that the abnormalities in carbohydrate metabolism are closely linked to, and perhaps dependent on, the abnormalities in lipoprotein transport in TLD. Long chain triglyceride restriction and MCT supplementation should be attempted in additional patients with the features of TLD to determine whether this is a generally effective therapeutic approach.


Subject(s)
Dietary Fats/administration & dosage , Insulin Resistance , Lipodystrophy/diet therapy , Lipoproteins/blood , Triglycerides/therapeutic use , Adolescent , Chylomicrons/blood , Dietary Fats/therapeutic use , Fatty Acids/administration & dosage , Glucagon/blood , Glucose , Humans , Insulin/blood , Lipids/blood , Lipodystrophy/blood , Male , Xanthomatosis/therapy
16.
J Clin Endocrinol Metab ; 77(2): 494-7, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8345057

ABSTRACT

Adrenal glands from a patient with ACTH-independent Cushing's syndrome, whose symptoms worsened during pregnancy and oral contraceptive use, were cultured in different concentrations of estradiol. Estradiol stimulated cortisol secretion in a dose-response manner in the absence of ACTH. Since immunoglobulins G from this patient did not stimulate corticosterone production in a mouse adrenal bioassay, an adrenal-stimulating immunoglobulin is unlikely to be the cause of adrenal hyperfunction in this case. This is the first description of estradiol stimulation of cortisol production by cultured adrenal cells in ACTH-independent Cushing's syndrome.


Subject(s)
Adrenal Cortex/pathology , Cushing Syndrome/metabolism , Estradiol/pharmacology , Hydrocortisone/biosynthesis , Pregnancy Complications/metabolism , Adrenal Cortex/drug effects , Adrenal Cortex/metabolism , Adult , Analysis of Variance , Animals , Biological Assay , Cells, Cultured , Corticosterone/biosynthesis , Dose-Response Relationship, Drug , Female , Humans , Immunoglobulin G/physiology , Male , Mice , Pregnancy
17.
J Clin Endocrinol Metab ; 79(5): 1450-6, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7962342

ABSTRACT

Hypertriglyceridemia is common among individuals with noninsulin-dependent diabetes mellitus (NIDDM), and heterozygous lipoprotein lipase (LPL) mutations may result in the syndrome of familial hypertriglyceridemia and low levels of high density lipoprotein (HDL) cholesterol. To test the hypothesis that heterozygous LPL mutations predispose to the hypertriglyceridemia and low HDL cholesterol levels observed among members of familial NIDDM families, we examined 36 members and 3 unrelated spouses selected from members of 20 pedigrees for triglyceride levels exceeding the age- and sex-specific 95th percentile. Eighteen pedigree members and 2 spouses were diabetic. LPL exons 1-9 were screened by single strand conformation polymorphism analysis. Six different variants were detected in exons 2, 3, 4, 8, and 9, including 4 (exons 3, 4, and 8) silent nucleotide substitutions. A common nonsense mutation (exon 9; Ser-->Ter) was present in 2 pedigrees, and a missense mutation (exon 2; Asp-->Asn) was also present in members of 2 pedigrees. Analysis of members of these families suggested an association of the exon 2 variant with hypertriglyceridemia, although this trend was no longer significant when individuals with diabetes were excluded from the analysis. The variant enzyme was not present among 83 random control individuals, and when expressed in COS-1 cells, it was similar to the wild type with respect to specific activity, heparin binding, and heat stability. Our data suggest that coding region mutations of the LPL gene cannot account for the elevated triglyceride and low HDL levels noted in diabetic individuals and their relatives in most NIDDM pedigrees, but the exon 2 Asn variant may contribute to the hypertriglyceridemia in some families.


Subject(s)
Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/genetics , Hypertriglyceridemia/enzymology , Hypertriglyceridemia/genetics , Lipoprotein Lipase/genetics , Adult , Aged , Aged, 80 and over , Alleles , Base Sequence , DNA/analysis , DNA/genetics , Diabetes Mellitus, Type 2/blood , Exons , Female , Genetic Testing , Genetic Variation , Heterozygote , Humans , Hypertriglyceridemia/blood , Male , Middle Aged , Molecular Sequence Data , Mutation , Pedigree , Triglycerides/blood
18.
J Clin Endocrinol Metab ; 82(5): 1572-81, 1997 May.
Article in English | MEDLINE | ID: mdl-9141552

ABSTRACT

Recombinant human interleukin-2 (rIL-2) is used to treat refractory cancers. During such treatment, patients develop severe hypocholesterolemia along with striking alterations in the concentration and composition of the circulating lipoproteins. The present study was undertaken to gather information about the pathogenesis of these abnormalities. Patients were studied before-, during- and after a 5-day course of high dose i.v. rIL-2. Whole plasma cholesterol was markedly reduced by rIL-2 administration (52%; P < 0.001), whereas the triglyceride concentration did not change. Thus, the lipoproteins became triglyceride enriched (P = 0.004). Low density lipoprotein cholesterol, apolipoprotein B (apoB), high density lipoprotein cholesterol, and apoA-I concentrations all decreased. Esterified cholesterol levels were markedly reduced. Total plasma apoE increased markedly, and two kinds of abnormal particles appeared: 1) beta-migrating, very low density lipoproteins; and 2) discoidal, apoE- and phospholipid-containing particles with abnormal density and electrophoretic mobility. The activities of two lipoprotein triglyceride hydrolases, lipoprotein lipase and hepatic lipase, fell significantly during treatment and returned promptly to pretreatment levels after rIL-2 was discontinued. Lecithin:cholesteryl acyltransferase (LCAT) activity also decreased significantly (64%) during treatment, but in contrast to the lipases, remained low for at least 5 days after the last dose of rIL-2 (P < 0.001). High dose i.v. rIL-2 induces severe dyslipidemia with deficiencies of both postheparin lipases and acute LCAT deficiency. Most, if not all, of the lipoprotein changes observed are explained by the LCAT deficiency that follows IL-2-induced hepatocellular injury and cholestasis.


Subject(s)
Interleukin-2/adverse effects , Lecithin Cholesterol Acyltransferase Deficiency/etiology , Lipase/deficiency , Lipoprotein Lipase/deficiency , Liver/enzymology , Apolipoprotein A-I/metabolism , Apolipoproteins B/blood , Apolipoproteins E/blood , Chemical and Drug Induced Liver Injury , Cholesterol/blood , Cholesterol Esters/blood , Humans , Interleukin-2/therapeutic use , Lipoproteins/blood , Lipoproteins, HDL/blood , Lipoproteins, HDL/ultrastructure , Microscopy, Electron , Neoplasms/drug therapy , Phospholipids/blood , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Triglycerides/blood
19.
Clin Pharmacol Ther ; 65(5): 473-82, 1999 May.
Article in English | MEDLINE | ID: mdl-10340912

ABSTRACT

OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of an infusion of SB 209670, a non-peptide endothelin-A/endothelin-B receptor antagonist. METHODS: The study was conducted in 2 parts. Part 1 was a placebo-controlled, single-blind, rising-dose crossover evaluation of the pharmacokinetics and safety of SB 209670 infused at doses that ranged from 0.2 to 1.5 mirog kg(-1) for approximately 8 hours in 17 healthy male volunteers. In part 2, renal hemodynamic effects of a 4-hour infusion of SB 209670 were assessed in 10 healthy male volunteers in a 2-period, period-balanced, single-blind, randomized, placebo-controlled crossover study. RESULTS: SB 209670 appeared to display linear kinetics over the dose range from 0.2 to 1.5 microg kg(-1) min(-1). The half-life was approximately 4 to 5 hours. Plasma immunoreactive endothelin-1 increased in an apparent dose-dependent manner. Mean renal hemodynamic responses (para-aminohippurate clearance) increased by approximately 15% relative to placebo (P = .007). Renal sodium excretion was similar during SB 209670 and placebo infusion. CONCLUSION: The pharmacokinetics of intravenous SB 209670 appeared to be linear, and infusion resulted in dose-related increases in immunoreactive endothelin-1. The lack of anti-natriuretic effect and the renal vasodilator response observed in this study indicate that SB 209670 does not possess any partial agonist activity. Further, the renal hemodynamic response supported a potential physiologic role for endogenous endothelin in the maintenance of renal vascular tone in humans.


Subject(s)
Endothelin Receptor Antagonists , Indans/pharmacology , Renal Circulation/drug effects , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Endothelin-1/blood , Humans , Indans/administration & dosage , Indans/pharmacokinetics , Infusions, Intravenous , Male , Middle Aged , Reference Values , Renal Plasma Flow, Effective/drug effects , Single-Blind Method , Vascular Resistance/drug effects
20.
Atherosclerosis ; 24(3): 491-9, 1976 Sep.
Article in English | MEDLINE | ID: mdl-971348

ABSTRACT

Lipoprotein lipase (LPL) activity was measured in adipose tissue, heart and diaphragm in Sprague--Dawley rats after estrogen therapy or orchiectomy. Enzyme activity was measured by incubation of tissue fragments with a triolein emulsion in the presence of serum and heparin. In confirmation of other work, depression of adipose tissue LPL followed estradiol treatment in pharmacologic or near-physiologic doses. Cardiac and diaphragmatic muscle LPL were increased. Estrogen-treated male animals showed growth retardation. However, they gained weight steadily and did not show significant differences in serum insulin, glucose of D-beta-hydroxybutyrate. The effects of estradiol in male animals were reversed by sequential fasting and re-feeding. At times during growth and aging in normal female rats, adipose tissue activity was decreased while cardiac and skeletal muscle activities were increased relative to males of the same age or body weight. Castration of male rats failed to reproduce the effect of estrogens on tissue lipoprotein lipase. These in vitro data suggest that exogenous estrogens may shift the flux of triglyceride fatty acids from storage in the adipose organ toward incorporation by muscle. These, and other data, raise the possibility that physiological estrogen secretion exerts a tonic influence over the synthesis and ultimate destination of triglyceride fatty acids.


Subject(s)
Adipose Tissue/enzymology , Diaphragm/enzymology , Estradiol/pharmacology , Lipoprotein Lipase/metabolism , Myocardium/enzymology , Testosterone/analogs & derivatives , Adipose Tissue/drug effects , Animals , Castration , Diaphragm/drug effects , Estradiol/analogs & derivatives , Heart/drug effects , Kinetics , Male , Organ Specificity , Rats , Testosterone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL